Travere Therapeutics Inc [NASDAQ: TVTX] closed the trading session at $27.31 on 2025-09-10. The day’s price range saw the stock hit a low of $24.9101, while the highest price level was $28.6927.
The stocks have a year to date performance of 148.72 percent and weekly performance of 39.27 percent. The stock has been moved at 50.68 percent over the last six months. The stock has performed 58.04 percent around the most recent 30 days and changed 80.50 percent over the most recent 3-months.
If compared to the average trading volume of 1.64M shares, TVTX reached to a volume of 12490680 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Travere Therapeutics Inc [TVTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TVTX shares is $36.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TVTX stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Travere Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 11, 2025. While these analysts kept the previous recommendation, Citigroup dropped their target price from $35 to $32. The new note on the price target was released on June 11, 2025, representing the official price target for Travere Therapeutics Inc stock. On October 21, 2024, analysts increased their price target for TVTX shares from 9 to 27.
The Price to Book ratio for the last quarter was 74.31, with the Price to Cash per share for the same quarter was set at 3.58.
TVTX stock trade performance evaluation
Travere Therapeutics Inc [TVTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.27. With this latest performance, TVTX shares gained by 58.04% in over the last four-week period, additionally plugging by 50.68% over the last 6 months – not to mention a rise of 56.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TVTX stock in for the last two-week period is set at 86.74, with the RSI for the last a single of trading hit 1.68, and the three-weeks RSI is set at 1.22 for Travere Therapeutics Inc [TVTX]. The present Moving Average for the last 50 days of trading for this stock 17.29, while it was recorded at 22.59 for the last single week of trading, and 18.09 for the last 200 days.
Travere Therapeutics Inc [TVTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Travere Therapeutics Inc [TVTX] shares currently have an operating margin of -51.12% and a Gross Margin at 81.87%. Travere Therapeutics Inc’s Net Margin is presently recorded at -50.64%.
Travere Therapeutics Inc (TVTX) Capital Structure & Debt Analysis
According to recent financial data for Travere Therapeutics Inc. ( TVTX), the Return on Equity (ROE) stands at -705.73%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -30.55%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Travere Therapeutics Inc’s Return on Invested Capital (ROIC) is -47.24%, showcasing its effectiveness in deploying capital for earnings.
Travere Therapeutics Inc (TVTX) Efficiency & Liquidity Metrics
Based on Travere Therapeutics Inc’s (TVTX) latest financial statements, the Debt-to-Equity Ratio is 12.20%, indicating its reliance on debt financing relative to shareholder equity.
Travere Therapeutics Inc (TVTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Travere Therapeutics Inc. (TVTX) effectively leverages its workforce, generating an average of -$439116.88 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.00% and a Quick Ratio of 1.98%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Travere Therapeutics Inc [TVTX] stock
With the latest financial reports released by the company, Travere Therapeutics Inc posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.54/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.08. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TVTX.
Travere Therapeutics Inc [TVTX]: Institutional Ownership
There are presently around $117.26%, or 118.14%% of TVTX stock, in the hands of institutional investors. The top three institutional holders of TVTX stocks are: BLACKROCK INC. with ownership of 7.64 million shares, which is approximately 9.8642%. ARMISTICE CAPITAL, LLC, holding 7.5 million shares of the stock with an approximate value of $$61.65 million in TVTX stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$60.58 million in TVTX stock with ownership which is approximately 9.5096%.
